ConductScience.org, home
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
API referenceFor AI assistants

Trial · NCT00097786

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDValsartan 160 mg od + Nateglinide 60 mg ac2,316
Overall StudySTARTEDValsartan 160 mg od + Placebo Nateglinide2,315
Overall StudySTARTEDNateglinide 60 mg ac + Placebo Valsartan2,329
Overall StudySTARTEDPlacebo2,346
Overall StudyComplete FU for Progression to DiabetesValsartan 160 mg od + Nateglinide 60 mg ac1,709
Overall StudyComplete FU for Progression to DiabetesValsartan 160 mg od + Placebo Nateglinide1,712
Overall StudyComplete FU for Progression to DiabetesNateglinide 60 mg ac + Placebo Valsartan1,734
Overall StudyComplete FU for Progression to DiabetesPlacebo1,762
Overall StudyComplete Follow-up for Extended CV EPsValsartan 160 mg od + Nateglinide 60 mg ac1,969
Overall StudyComplete Follow-up for Extended CV EPsValsartan 160 mg od + Placebo Nateglinide1,985
Overall StudyComplete Follow-up for Extended CV EPsNateglinide 60 mg ac + Placebo Valsartan1,987
Overall StudyComplete Follow-up for Extended CV EPsPlacebo2,015
Overall StudyComplete Follow-up for Core CV EPsValsartan 160 mg od + Nateglinide 60 mg ac1,948
Overall StudyComplete Follow-up for Core CV EPsValsartan 160 mg od + Placebo Nateglinide1,963
Overall StudyComplete Follow-up for Core CV EPsNateglinide 60 mg ac + Placebo Valsartan1,966
Overall StudyComplete Follow-up for Core CV EPsPlacebo1,988
Overall StudyCOMPLETEDValsartan 160 mg od + Nateglinide 60 mg ac2,020
Overall StudyCOMPLETEDValsartan 160 mg od + Placebo Nateglinide2,023
Overall StudyCOMPLETEDNateglinide 60 mg ac + Placebo Valsartan2,016
Overall StudyCOMPLETEDPlacebo2,036

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00097786/flow

API referenceFor AI assistants